Wednesday, March 18, 2015


Microsemi Buys Vitesse Semiconductor For $389M
Aliso Viejo-based Microsemi and Camarillo-based Vitesse Semiconductor said this morning that Microsemi has agreed to buy Vitesse, in a deal worth $389M. The two said that Miicrosemi will pay $5.28 per share for Vitesse--a 32 percent premium to Vitesse's average closing price during the last 30 trading days--and will allow the companies to offer up a broader solution to the market. Vitesse is a developer of high speed, networking semiconductors. Vitesse was founded in 1984. Microsemi is being ad (More info...)
posted on Wednesday, March 18, 2015(Full story)

Vroozi Debuts Mobile Procurement Software
Los Angeles-based Vroozi, a developer of cloud-based, procurement software for the enterprise, said this morning that it has launched a responsive platform which helps employees search, request, approve and order goods and services via smartphone, tablet, or any website. Vroozi is led by Steve Olds. Vroozi said its platform is aimed at small and medium sized businesses, who want to keep track of office spend, leverage discount pricing and interact with their suppliers electronically.
posted on Wednesday, March 18, 2015(Full story)

Adtile Launches Mobile VR Software
San Diego-based Adtile Technologies has launched a new software product, which the company says allows smartphone users to experience virtual reality without special goggles or hardware. According to Adtile, its new product allows native and web-based app users to "walk" through a digital space. Adtile is led by Nils Forsblom. The company said the new product is aimed at the publishing, fashion, real estate, retail, entertainment, automotive, science and other industries.
posted on Wednesday, March 18, 2015(Full story)

Ignyta Raises $42M From Teva, Buys Oncology Assets
San Diego-based Ignyta, a bio pharmaecuicals firm developing products for treating cancer, said late Tuesday that it has received a $42M equity investment from Teva Pharmaceutical, and acquired four oncology R&D assets from the company. The deal is comprised of the purchase of 1.5 million shares of Ignyta common stock by Teva. The four development programs being purchased by Ignyta include a small molecule inhibitor of BRAF, EGFR and RET; a pseudo-irreversible inhibitor of AXL and cMET; a nanofo (More info...)
posted on Wednesday, March 18, 2015(Full story)